Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
Myriad hailed Genesight, a pharmaco-genomics (PGx) test for depression drugs, as its entrance into a giant untapped market when they acquired the product. Subsequently the product failed its primary ...
For years, Madeline Bohlman lit up the pageant stage, radiating confidence in dazzling gowns as crowds erupted in applause, leading her to win not one, but two titles. But behind her captivating smile ...
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...
On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:MYGN) said Unitedhealth Group Inc’s (NYSE:UNH) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results